Tissue repair using allogeneic dermal fibroblasts

The method of any preceding claim, in which the fibroblasts are passaged.

The method of any preceding claim, wherein the defect is a rhytid, stretch mark, a depressed scar, a cutaneous depression of non-traumatic origin or an under-development of the lip.

The method of any preceding claim, wherein the suspension further comprises fibrin in an amount effective to form an injectable.

The method of any preceding claim, wherein the suspension further comprises collagen and/or hyaluronic acid.

The method of any preceding claim, in which the subject is human.

The method of any preceding claim wherein between 104 and 108, for example between 106 and 108, preferably about 1-5×107, for example 1×107 4×107, fibroblasts are injected.

The method of any preceding claim wherein a volume of about 1 ml of suspension is injected.

A method according to any preceding claim wherein

• a) The fibroblasts are suspended in HypoThermosol® preservation medium;
• and
• b) about 1×107 or 4×107 fibroblasts are injected in about 1 ml of suspension.

Use of allogeneic dermal fibroblasts, optionally including a preservation medium which is HypoThermosol®, preferably HypoThermosol® FRS (Registered Trade Mark BioLife Solutions, Inc.), in the treatment of subcutaneous or dermal tissue defects.

Use of allogeneic dermal fibroblasts, optionally including a preservation medium which is HypoThermosol®, preferably HypoThermosol® FRS (Registered Trade Mark BioLife Solutions, Inc.), in the manufacture of a medicament for the cosmetic treatment of subcutaneous or dermal tissue defects.

A composition for the augmentation of subcutaneous or dermal tissue in a subject, which comprises a suspension of allogeneic dermal fibroblasts in a preservation medium which is HypoThermosol®, preferably HypoThermosol® FRS (Registered Trade Mark BioLife Solutions, Inc.)